share_log

STRATA Skin Sciences to Report First Quarter 2024 Financial Results on May 15, 2024 and Provide Corporate Update

STRATA Skin Sciences to Report First Quarter 2024 Financial Results on May 15, 2024 and Provide Corporate Update

STRATA Skin Sciences将于2024年5月15日公布2024年第一季度财务业绩并提供公司最新情况
GlobeNewswire ·  05/08 20:15

HORSHAM, Penn., May 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2024 financial results on Wednesday, May 15, 2024 after the market close.

宾夕法尼亚州霍舍姆,2024年5月8日(GLOBE NEWSWIRE)——致力于开发、商业化和营销用于治疗皮肤病的创新产品的医疗技术公司STRATA Skin Sciences, Inc.(“STRATA” 或 “公司”)(纳斯达克股票代码:SSKN)宣布,将在2024年5月15日星期三收盘后公布2024年第一季度财务业绩。

STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, May 15, 2024 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session.

STRATA管理层将于美国东部时间2024年5月15日星期三下午 4:30 举行电话会议,审查财务业绩并提供公司发展的最新情况。管理层发表正式讲话后,将举行问答环节。

To listen to the conference call, interested parties within the U.S. should dial 1-877-270-2148 (domestic) or 1-412-902-6510 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.

要收听电话会议,美国境内的有关各方应拨打1-877-270-2148(国内)或1-412-902-6510(国际)。所有来电者应在预定开始时间前大约10分钟拨打电话,并要求参加STRATA Skin Sciences, Inc.的电话会议。

The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences 1Q24 Earnings Webcast.

电话会议还将通过网络直播播出,可在STRATA Skin Sciences第二季度财报网络直播中观看。

The webcast replay will be available until November 15, 2024 and can be accessed through the above link.

网络直播重播将持续到2024年11月15日,可通过上述链接观看。

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System.

关于 STRATA 皮肤科学公司
STRATA Skin Sciences是一家医疗技术公司,致力于开发、商业化和营销用于各种皮肤病的办公室内治疗的创新产品,例如牛皮癣、白癜风和痤疮。其产品包括 XTRAC 准分子激光、VTRAC 灯具系统和 TheraCleaRX 痤疮治疗系统。

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA's popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

STRATA 很自豪能够通过其独特的合作伙伴计划在美国提供这些令人兴奋的技术。STRATA 广受欢迎的合作方式包括按治疗成本结构收取费用而不是设备购买、安装和使用设备、为诊所人员提供现场培训、设备服务和维护、专职客户和客户服务人员以及合作广告支持,以帮助提高认识并在诊所内推广该计划。

Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements, the Company's ability to launch and sell products recently acquired or to be developed in the future, the Company's ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company's ability to build a leading franchise in dermatology and aesthetics, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and .

安全港
本新闻稿包括1995年《证券诉讼改革法》所指的 “前瞻性陈述”。这些陈述包括但不限于公司的计划、目标、期望和意图,并可能包含 “将”、“可能”、“寻求” 和 “期望” 等暗示未来事件或趋势的词语。这些声明、公司推出和销售最近收购或将要开发的产品的能力、公司开展社交媒体营销活动、直接面向消费者营销活动的能力以及公司建立领先的皮肤病学和美容特许经营权的能力,均基于公司当前的预期,本质上受重大的不确定性和环境变化的影响。由于财务、经济、业务、竞争、市场、监管、不利的市场条件、劳动力供应短缺或因财政、政治因素、国际冲突、应对措施或影响公司、医疗器械行业以及我们的一般客户和患者的条件而导致的供应链中断,以及公司在10-Q和10-K表中提出的更具体的风险和不确定性,实际业绩可能与公司的预期存在重大差异。鉴于此类不确定性,任何或所有这些前瞻性陈述都可能被证明是不正确或不可靠的。本新闻稿中的声明是自本新闻稿发布之日起发表的,即使公司随后在其网站或其他地方发布了声明。公司没有义务更新或修改这些声明以反映本新闻稿发布之日之后发生的事件或情况。该公司敦促投资者仔细审查其在www.sec.gov上提供的美国证券交易委员会披露信息,以及.

Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com

投资者联系人:
CORE IR
516-222-2560
IR@strataskin.com


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发